Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; Cancer Center, China Medical University Hospital, Taichung, Taiwan; College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan.
Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung, Taiwan; Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan.
Biochem Pharmacol. 2020 Apr;174:113811. doi: 10.1016/j.bcp.2020.113811. Epub 2020 Jan 16.
Pyruvate kinase M2 (PKM2) is a key enzyme responsible for the final step of glycolysis. It is still unclear whether PKM2 is involved in reactive oxygen species (ROS)-mediated cytotoxicity in gastrointestinal cancer, and what mechanisms are involved. One duodenal (AZ521) and two gastric (NUGC and SCM-1) cancer cell lines were treated with an indole-3-carbinol derivative OSU-A9, which caused cytotoxicity in acute myeloid leukemia through ROS generation. OSU-A9 caused a dose- and time-dependent cytotoxicity and induced apoptosis in duodenal and gastric cancer cells through ROS generation. Pretreatment with ROS scavengers rescued cancer cells from apoptosis and concomitant poly (ADP-ribose) polymerase cleavage, implying a key role of ROS in OSU-A9-induced cell death. Moreover, OSU-A9-induced ROS generation decreased protein levels of p-PKM2, and this effect was rescued by pretreatment with ROS scavengers. Interestingly, p-PKM2 protein levels decreased in the cell nucleus rather than in the cytoplasm. PKM2 overexpression partially rescued the survival of duodenal and gastric cancer cells treated with OSU-A9. Furthermore, the anticancer activity of OSU-A9 extended in vivo, as OSU-A9 administered by oral gavage suppressed the growth of AZ521 xenograft tumors in nude mice without obvious toxicity. In conclusion, OSU-A9 inhibited duodenal and gastric cancer cell proliferation through ROS generation and caused a subsequent decrease in nuclear p-PKM2 protein. These findings provide evidence for the non-canonical activity of PKM2 in cancer cell survival. Furthermore, they highlight the potential role of PKM2 as a future therapeutic target for duodenal and gastric cancer.
丙酮酸激酶 M2(PKM2)是糖酵解最后一步的关键酶。目前尚不清楚 PKM2 是否参与胃肠道癌症中的活性氧(ROS)介导的细胞毒性,以及涉及哪些机制。我们用一种吲哚-3-甲醇衍生物 OSU-A9 处理了一种十二指肠(AZ521)和两种胃(NUGC 和 SCM-1)癌细胞系,OSU-A9 通过产生 ROS 导致急性髓系白血病的细胞毒性。OSU-A9 引起剂量和时间依赖性的细胞毒性,并通过产生 ROS 诱导十二指肠和胃癌细胞凋亡。ROS 清除剂预处理可挽救癌细胞免于凋亡和伴随的多聚(ADP-核糖)聚合酶裂解,表明 ROS 在 OSU-A9 诱导的细胞死亡中起关键作用。此外,OSU-A9 诱导的 ROS 生成降低了 p-PKM2 的蛋白水平,而 ROS 清除剂预处理可挽救这种作用。有趣的是,p-PKM2 蛋白水平在细胞核中而不是细胞质中降低。PKM2 过表达部分挽救了用 OSU-A9 处理的十二指肠和胃癌细胞的存活。此外,OSU-A9 的抗癌活性在体内得到扩展,因为口服灌胃给予 OSU-A9 可抑制裸鼠中 AZ521 异种移植肿瘤的生长,而无明显毒性。总之,OSU-A9 通过产生 ROS 抑制十二指肠和胃癌细胞的增殖,并导致随后核内 p-PKM2 蛋白减少。这些发现为 PKM2 在癌细胞存活中的非经典活性提供了证据。此外,它们强调了 PKM2 作为未来治疗十二指肠和胃癌的潜在靶点的作用。